Trial Profile
Optimal strategy in K-ras wild type metastatic colorectal cancer patients: cetuximab plus FOLFIRI followed by FOLFOX+/- cetuximab (GOIM multicenter program)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Oct 2017
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms CAPRI-GOIM
- 12 Sep 2017 Mature survival data (cut off date: April 30, 2017; n=98) presented at the 42nd European Society for Medical Oncology Congress
- 12 Sep 2017 Results of liquid biopsy analysis (n=96) presented at the 42nd European Society for Medical Oncology Congress
- 12 Sep 2017 Results assessing Eph A2 expression is a predictive biomarker of treatment efficacy, presented at the 42nd European Society for Medical Oncology Congress